Answers are grounded in this paper and cite their sources.
Fibrosis-4 (FIB4) is a recommended noninvasive test to assess hepatic fibrosis among patients with metabolic dysfunction-associated steatotic liver disease (MASLD). Here, we used FIB4 trajectory over time (ie, "slope" of FIB4) as a surrogate marker of liver fibrosis progression and examined if FIB4 slope is associated with clinical and genetic factors among individuals with clinically defined MASLD within the Million Veteran Program Cohort.
No takes yet. Share an insight, caveat, or question.
Kaplan et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: